Teva’s Pre-Clinical Stage Acceptance Process

Within 2 weeks of submission of your non-confidential information package, we will complete our initial review and one of our partnering directors will respond to you.

Submit your idea through our Project Submission Wizard.

If your product meets our criteria, we'll ask you to enter into a confidentiality agreement and submit a complete product package.

If you’d like to request a confidentiality agreement template or submit your own draft, please contact your dedicated partnering officer.

Once we receive your complete product package, we’ll forward it to our product evaluation committee, which meets weekly.

Within two to three weeks of submitting the complete package to Teva, the partnering director will inform you whether we would like to continue the process toward establishing a mutually beneficial agreement.

Following the approval of the Product Evaluation Committee, we typically conduct Experimental Due Dillegence on your product and, to do so, we will enter into a material transfer agreement (MTA), which allows us to test your product. We’ll request all data and materials in order to confirm and expand upon your results.

If you would like to request a MTA template or submit your own draft, please contact your dedicated partnering officer.

Experimental Due Diligence

Once we receive your signed MTA and all relevant information, including material necessary for testing, we will begin Experimental Due Diligence including pharmacological testing in which we will work with you and confirm and expand the test(s) that led to your demonstrated major finding(s). This step may take 3-6 months.

Parallel to the MTA and Experimental Due Diligence, we will begin business negotiations with the goal of achieving a win-win situation between Teva and our partner. We are very flexible in the appropriate deal structure, and we are committed to proceeding quickly and expeditiously.

Pre-Clinical Studies

Following the Experimental Due Diligence, the successful conclusion of the Business Negotiations and then entering into a contractual relationship, in the next stage, we'll conduct additional, expanded animal pharmacological studies to explore the full potential of the product, in consultation with you, external experts and our world-class Scientific Advisory Board.

IND/CTA Enabling Studies

If the Pre-clinical testing concludes successfully, we begin formal IND/CTA enabling clinical development.

During this phase we'll conduct the tests required by the FDA and EMEA regulatory agencies, among others, with a goal of getting into first-in-man as quickly as possible.

Clinical Development

Throughout testing - which comprises several phases and requires a number of years to complete - Teva Partners is dedicated to keeping you informed through effective communication and transparent processes. Whether performed in-house or outsourced, the goals of testing include

• Proving a drug works against the disease in the general population and shows strategic advantages over existing therapies
• Providing substantial evidence of efficacy and safety
• Confirming optimal dosage quantity and frequency
• Conducting large-scale staticstical analyses and reporting
• And more